DART project: novel mRNA delivery systems for vaccines

BLOG > News & Events > DART project: novel mRNA delivery systems for vaccines

DART Project “Development of novel mRNA delivery systems for vaccine applications.”

The project aims to “develop new mRNA delivery systems for vaccine applications”. The objective is to create mRNA delivery systems based on ionizable, biocompatible and innovative polymers, as an alternative to the lipid nanoparticles (LNPs) currently used in RNA vaccines. The goal is to obtain a new mRNA vaccine formulation that is more effective, more stable, better tolerated and less reactogenic than the lipid nanoparticles used in current COVID-19 vaccines. The polymers will be synthesized, formulated with mRNA as polymeric or lipopolymeric nanoparticles, and tested in a vaccine model.

The DART project is part of the IPCEI Health Med4Cure, in which OZ Biosciences takes part as an indirect partner (BPI contract no. DOS0258067 - DOS0258068). This project has been funded by the French State as part of France 2030.

For more information about the project please contact Olivier Zelphati, CEO at OZ Biosciences; ozelphati@ozbiosciences.com.

Related Articles

Eurostars Project CAPSULIX: mRNA and LNPs for engineered cell therapy

The consortium composed of OZ Biosciences, ExploRNA, and Miltenyi Biotec will deliver a novel cell-based therapy manufacturing platform to treat cancer with CAR expressing T cells.

Read more

Our cationic poloxamers patent is now granted in Australia

Patent No. AU2020314617, “CATIONIC POLOXAMERS AND THEIR USE IN TRANSDUCTION,” covers our method for synthetically modifying poloxamers to confer additional biological properties...

Read more

Partnership Opportunities

As new R&D programs take shape and funding opportunities emerge, we would like to highlight that we’re open to multiple collaboration models.

Read more